| Drug ID: | Drug136 |
|---|---|
| Drug Name: | Filgotinib |
| CID: | 49831257 |
| DrugBank ID: | DB14845 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT03201445, , NCT06865417, , NCT02914522, , NCT02914535, , NCT05479058, , NCT05817942, , NCT03046056, , NCT03077412, , NCT02914561, , NCT02048618 |
| Molecular Formula: | C21H23N5O3S |
| Molecular Weight: | 425.5 g/mol |
| Isomeric SMILES: | C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5 |
| Synonyms: | Filgotinib; 1206101-20-3; GLPG0634; 1206161-97-8; GLPG-0634; N-(5-(4-((1,1-dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide; Filgotinib (GLPG0634); N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide; N-[5-[4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide; Filgotinib(GLPG0634) |
| Phase 0: | 0 |
| Phase 1: | 6 |
| Phase 2: | 14 |
| Phase 3: | 17 |
| Phase 4: | 7 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1090 | 49831257 | Filgotinib | 3716 | JAK1 | Homo sapiens (human) | Inhibitor | |
| dt1091 | 49831257 | Filgotinib | 3717 | JAK2 | Homo sapiens (human) | 24417533 | Inhibition |
| dt1092 | 49831257 | Filgotinib | 3717 | JAK2 | Homo sapiens (human) | 24006460 | Inhibition |
| dt1093 | 49831257 | Filgotinib | 3716 | JAK1 | Homo sapiens (human) | 24417533 | Inhibition |
| dt1094 | 49831257 | Filgotinib | 3716 | JAK1 | Homo sapiens (human) | 24006460 | Inhibition |
| dt1095 | 49831257 | Filgotinib | 3718 | JAK3 | Homo sapiens (human) | 24006460 | Inhibition |
| dt1096 | 49831257 | Filgotinib | 2049 | EPHB3 | Homo sapiens (human) | Inhibitor | |
| dt1097 | 49831257 | Filgotinib | 3716 | JAK1 | Homo sapiens (human) | 24818516 | Tyrosine-protein kinase JAK1 inhibitor |
| dt1098 | 49831257 | Filgotinib | 3717 | JAK2 | Homo sapiens (human) | 33741556 | Tyrosine-protein kinase JAK2 inhibitor |
| dt1099 | 49831257 | Filgotinib | 7297 | TYK2 | Homo sapiens (human) | 33741556 | Tyrosine-protein kinase TYK2 inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06865417 | A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis | PHASE3 | NOT_YET_RECRUITING | Alfasigma S.p.A. | Ulcerative Colitis | DRUG: Filgotinib | Details |
| NCT02914522 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | Gilead Sciences | Ulcerative Colitis | DRUG: Filgotinib|DRUG: PTM filgotinib | Details |
| NCT02914535 | Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | PHASE3 | ACTIVE_NOT_RECRUITING | Alfasigma S.p.A. | Ulcerative Colitis | DRUG: Filgotinib|DRUG: Placebo | Details |
| NCT05479058 | A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission | PHASE3 | TERMINATED | Galapagos NV | Ulcerative Colitis | DRUG: Filgotinib|DRUG: Placebo | Details |
| NCT05817942 | Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) | None | RECRUITING | Alfasigma S.p.A. | Ulcerative Colitis | DRUG: Filgotinib | Details |
| NCT03046056 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) | PHASE2 | COMPLETED | Gilead Sciences | Small Bowel Crohn's Disease | DRUG: Filgotinib|DRUG: Placebo to match filgotinib | Details |
| NCT06246123 | A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants | None | RECRUITING | Eisai Korea Inc. | Arthritis, Rheumatoid|Colitis, Ulcerative | OTHER: Non-interventional | Details |
| NCT03077412 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease | PHASE2 | COMPLETED | Gilead Sciences | Fistulizing Crohn's Disease | DRUG: Filgotinib|DRUG: Placebo to match filgotinib | Details |
| NCT02914561 | Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease | PHASE3 | COMPLETED | Galapagos NV | Crohn's Disease | DRUG: Filgotinib|OTHER: Placebo | Details |
| CTRI/2018/07/014719 | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to_Evaluate the Testicular Safety of Filgotinib in Adult Males with_Moderately to Severely Active Inflammatory Bowel Disease. | PHASE2 | Not Recruiting | Gilead Sciences Inc | Health Condition 1: K509- Crohns disease, unspeci… | Intervention1: Filgotinib 200mg oral tablet : Fil… | Details |
| NCT05653791 | Early Intestinal Ultrasound in Predicting Treatment Response to Filgotinib in Ulcerative Colitis | None | UNKNOWN | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Ulcerative Colitis | DIAGNOSTIC_TEST: Intestinal ultrasound | Details |
| NCT03201445 | Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease | PHASE2 | TERMINATED | Galapagos NV | Inflammatory Bowel Disease | DRUG: Filgotinib|DRUG: Placebo|DRUG: Standard of … | Details |
| NCT02048618 | Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease | PHASE2 | COMPLETED | Galapagos NV | Crohn's Disease | DRUG: GLPG0634|DRUG: Placebo | Details |
| NCT04624230 | Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | PHASE3 | RECRUITING | Pfizer | Ulcerative Colitis | DRUG: tofacitinib | Details |
| NCT06651281 | Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) | PHASE3 | RECRUITING | Merck Sharp & Dohme LLC | Crohn Disease|Colitis, Ulcerative | DRUG: Tulisokibart|DRUG: Placebo to tulisokibart | Details |
| NCT04985968 | The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis | PHASE3 | TERMINATED | InDex Pharmaceuticals | Ulcerative Colitis | DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… | Details |
| NCT06681181 | A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants | PHASE1 | RECRUITING | GlaxoSmithKline | Colitis, Ulcerative | DRUG: GSK4528287|DRUG: Placebo | Details |
| NCT06353828 | Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients | PHASE2 | ACTIVE_NOT_RECRUITING | CannaMore Biotechs | Ulcerative Colitis | DRUG: CBD, synthetic form|DRUG: Placebo | Details |
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT01011322 | A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis | PHASE2 | UNKNOWN | Lipid Therapeutics GmbH | Ulcerative Colitis|Large Intestine|Diarrhea|Abdom… | DRUG: LT-02|DRUG: placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgo…
PMID: 35614292
Year: 2022
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: The phase 2 MANTA and MANTA-RAy studies were developed in consultation with global regulatory authorities to investigate potential impa…
Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerat…
PMID: 34791103
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Filgotinib is a small molecule that selectively inhibits Janus kinase [JAK] type 1. It is already approved for the treatment of …
Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and…
PMID: 34741617
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Pro-inflammatory cytokines are dysregulated in Crohn's disease (CD) and could serve as surrogate markers to improve diagnostic and therap…
Filgotinib: First Approval
PMID: 33237566
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Filgotinib (Jyseleca((R))) is an oral, ATP-competitive, reversible JAK1 preferential inhibitor that is being developed by Galapagos NV and Gilead Sci…
Filgotinib for the treatment of Crohn's disease
PMID: 29448862
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Inflammatory bowel diseases, such as Crohn's disease (CD) and ulcerative colitis (UC), are widespread diseases (with an estimated 2.2 million Europea…
IBD-mediated oxidative cyclization of pyrimidinylhydrazones and concurrent Dimr…
PMID: 24367427
Year: 2013
Relationship Type:
Association
Score: 6.1
BACKGROUND AND AIMS: To investigate the macro- and microstructural changes of bone in patients with inflammatory bowel disease [IBD] and to define t…